{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:53:23Z","timestamp":1781222003402,"version":"3.54.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,26]],"date-time":"2016-09-26T00:00:00Z","timestamp":1474848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","annemergmed.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Emergency Medicine"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.annemergmed.2016.09.032","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T00:47:14Z","timestamp":1480466834000},"page":"541-550.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["CHA 2 DS 2 -VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban"],"prefix":"10.1016","volume":"69","author":[{"given":"W. Frank","family":"Peacock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Tamayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Sicignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen P.","family":"Hopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annemergmed.2016.09.032_bib1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1586\/erc.12.161","article-title":"Stroke risk stratification scores in atrial fibrillation. Current recommendations for clinical practice and future perspectives","volume":"11","author":"Durrant","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib2","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jacc.2010.05.028","article-title":"Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis","volume":"56","author":"Marinigh","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib3","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1161\/01.STR.28.2.311","article-title":"Atrial fibrillation and stroke. Mortality and causes of death after the first acute ischemic stroke","volume":"28","author":"Kaarisalo","year":"1997","journal-title":"Stroke"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib5","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/europace\/eur126","article-title":"Bleeding risk assessment and management in atrial fibrillation patients. A position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis","volume":"13","author":"Lip","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib6","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/europace\/euq080","article-title":"The likelihood of decreasing strokes in atrial fibrillation patients by strict application of guidelines","volume":"12","author":"Pisters","year":"2010","journal-title":"Europace"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib7","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1161\/01.STR.0000153002.56324.8c","article-title":"Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated?","volume":"36","author":"Miller","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib8","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/europace\/eus305","article-title":"2012 focused update of the\u00a0ESC\u00a0Guidelines for the management of atrial fibrillation: an update\u00a0of\u00a0the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association","volume":"14","author":"Camm","year":"2012","journal-title":"Europace"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib9","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1161\/CIR.0000000000000041","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib10","unstructured":"National Institute for Health and Care Excellence. Atrial fibrillation: clinical guidelines June 2014. Available at: http:\/\/www.nice.org.uk\/guidance\/cg180\/evidence\/atrial-fibrillation-update-full-guideline-243739981. Accessed July 12,\u00a02015."},{"key":"10.1016\/j.annemergmed.2016.09.032_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib12","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacc.2014.11.046","article-title":"Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-Vasc score (beyond sex) receive oral anticoagulation?","volume":"65","author":"Chao","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib13","unstructured":"The Military Health System. 2012 Military Health System stakeholders report. Available at: http:\/\/www.health.mil\/\u223c\/media\/MHS\/Report%20Files\/Optimized%202012_MHS_Stakeholders_Report120207.ashx. Accessed October 25,\u00a02015."},{"key":"10.1016\/j.annemergmed.2016.09.032_bib14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.7205\/MILMED-D-12-00168","article-title":"Leveraging the Military Health System as a laboratory for health care reform","volume":"178","author":"Dorrance","year":"2013","journal-title":"Mil Med"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib15","unstructured":"United States Census Bureau. Age and sex composition in the United States: 2011. Available at: http:\/\/www.census.gov\/population\/age\/data\/2011comp.html. Accessed May 19,\u00a02014."},{"key":"10.1016\/j.annemergmed.2016.09.032_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/clc.22373","article-title":"Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban","volume":"38","author":"Tamayo","year":"2015","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib17","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/pds.2109","article-title":"An automated database case definition for serious bleeding related to oral anticoagulant use","volume":"20","author":"Cunningham","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1161\/CIRCULATIONAHA.114.012061","article-title":"Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation","volume":"131","author":"Graham","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib19","series-title":"Detection and Evaluation of Major Bleeding in Atrial Fibrillation or Total Hip or Knee Replacement Patients Treated With Rivaroxaban","author":"Tamayo","year":"2014"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib20","doi-asserted-by":"crossref","unstructured":"Alpesh A, Keshishian A, Xie L, et\u00a0al. Early comparison of major bleeding, stroke and associated medical costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban or warfarin. Abstract presented at: American Society of Hematology; December 7, 2015; Orlando, FL. Abstract 745. Available at: https:\/\/ash.confex.com\/ash\/2015\/webprogram\/Paper85765.html. Accessed February 10,\u00a02016.","DOI":"10.1182\/blood.V126.23.745.745"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib21","doi-asserted-by":"crossref","first-page":"h5876","DOI":"10.1136\/bmj.h5876","article-title":"Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study","volume":"351","author":"Staerk","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib22","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2217\/pgs.14.153","article-title":"Genotype and risk of major bleeding during warfarin treatment","volume":"15","author":"Kawai","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib23","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1161\/STROKEAHA.114.006016","article-title":"Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin","volume":"45","author":"Alonso","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib24","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/phar.1597","article-title":"Predictors of gastrointestinal bleeding among patients with atrial fibrillation after\u00a0initiating dabigatran therapy","volume":"35","author":"Lauffenburger","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib25","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.amjmed.2014.01.044","article-title":"Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans","volume":"127","author":"Lane","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib26","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib27","unstructured":"Xarelto [prescribing label]. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202439s001lbl.pdf. Accessed October 25,\u00a02015."},{"key":"10.1016\/j.annemergmed.2016.09.032_bib28","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jacc.2013.11.013","article-title":"Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)","volume":"63","author":"Goodman","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib29","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1160\/TH12-03-0175","article-title":"The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study","volume":"107","author":"Olesen","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib30","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1586\/14779072.2013.815423","article-title":"Is bleeding a necessary evil? the inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation","volume":"11","author":"Myat","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib31","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/eurheartj\/ehs314","article-title":"The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy","volume":"34","author":"Coppens","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib32","doi-asserted-by":"crossref","first-page":"603.e1","DOI":"10.1016\/j.amjmed.2011.09.030","article-title":"Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation","volume":"125","author":"Mason","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib33","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1161\/STROKEAHA.110.590257","article-title":"Identifying patients at high risk for stroke despite anticoagulation","volume":"41","author":"Lip","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib34","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMp0907122","article-title":"Weighing benefits and risks\u2014the FDA's review of prasugrel","volume":"361","author":"Unger","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib35","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1056\/NEJMp1103050","article-title":"Anticoagulant options\u2014why the FDA approved a higher but not a lower dose of dabigatran","volume":"364","author":"Beasley","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2016.09.032_bib36","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A\u00a0novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"}],"container-title":["Annals of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064416311118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064416311118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T16:08:31Z","timestamp":1601222911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196064416311118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0196064416311118"],"URL":"https:\/\/doi.org\/10.1016\/j.annemergmed.2016.09.032","relation":{},"ISSN":["0196-0644"],"issn-type":[{"value":"0196-0644","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CHA2DS2-VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban","name":"articletitle","label":"Article Title"},{"value":"Annals of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annemergmed.2016.09.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American College of Emergency Physicians. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}